The average antipsychotic prescription rate in these depressed outpatients in Asia was 25.8% (N5213). As shown in Figure 1A , there was a tendency for the percentage prescription of second-generation antipsychotics to be greater than that of first-generation antipsychotics in all countries/ regions, and the percentage of depressed outpatients receiving any antipsychotic ranged from 15.5% (Thailand) to 61.3% (Indonesia). The percentage of prescriptions for adjunctive antipsychotics in Indonesia was much greater than in any other country/region (x 2 546.652, p,0.0001). The percentage of depressed outpatients receiving second-generation antipsychotics ranged from 6.3% (Thailand) to 44.7% (Indonesia), compared with 0.0% (Singapore) to 21.3% (Indonesia) for firstgeneration antipsychotics. As shown in Figure 1B , the average chlorpromazine-equivalent dose for depressed outpatients prescribed with antipsychotics ranged from 61.2 mg (Japan) to 189.8 mg (Indonesia). Especially, the chlorpromazineequivalent dose for depressed outpatients in Indonesia was greater than that in the other countries (F52.908, p50.003). More specifically, the average chlorpromazine-equivalent 
Moreover, international differences in clinical manifestations of depressive disorder can be attributed to the pathofacilitative or pathoreactive effects of specific cultures (4). In addition, adjunctive antipsychotic prescriptions for depressed outpatients can be influenced by psychopathology, cultural effects, clinical practice guidelines, national insurance systems, clinicians' preferences, and other factors. To understand the pattern of antipsychotic supplementation for depressed outpatients in Asia, a further study identifying the most important contributing factors is needed.
TO THE EDITOR: The article by William W. Eaton, Ph.D., and colleagues (1), published in the March 2015 issue of the Journal, described the case of an adolescent with complex autoimmune illness, whose psychotic symptoms were found to significantly improve after a gluten-free diet and pharmacological treatment with antidepressant and antipsychotic medication. The authors discussed possible mechanisms implied in patient's response to the gluten-free diet, arguing for immunological abnormalities and neuroinflammatory processes that may have played a role in the pathogenesis of schizophrenia and autoimmune conditions.
The patient had two previous diagnoses of major depressive disorder with psychotic features, and the family had a history of affective disorder, with both parents having a history of seasonal affective disorder and two grandparents having experienced bouts of depression. In addition, the patient was treated with low dosages of antipsychotics (previously 5 mg/day of aripiprazole, afterward 1.5 mg/day of risperidone) along with antidepressants (previously 10 mg/day of escitalopram, afterward 150 mg/day of venlafaxine). Taken as a whole, these elements suggest the possibility of an affective diathesis rather than schizophrenia. This diagnostic interpretation would not disconfirm the presence of interplaying immunoinflammatory patterns underlying the genesis of complex autoimmune and psychiatric conditions, like major depressive disorder, as these have been consistently reported (2) along with a positive response following a gluten-free diet in depressed patients (3) .
The patient's gluten sensitization does not conform to a recognized gluten-related disorder subtype. However, celiac disease is suggested by the presence of anti-gliadin antibodies and the relevant autoimmune family history (unfortunately, human leukocyte antigen typing and duodenal histology are unknown), while positivity to specific immunoglobulin E underlines a possible Th2 allergic pathway. Neurological and mood alterations of various severity have been widely reported in all gluten-related disorders, as possible extraintestinal symptoms improving during a gluten-free dietetic regimen. Ultimately, on the basis of the current knowledge and the absence of gluten-free diet side effects, dietotherapy should be further investigated in addition to current pharmacological treatments (4, 5) .
